+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 65Years
All Genders
ID04147286

Double-blind, Randomized, Placebo-controlled Trial of 40 mg Atorvastatin to Reduce Lung Inflammation After Tuberculosis Treatment in Adults With and Without HIV

Led by University of Cape Town · Updated on 2024-08-23

220

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of atorvastatin, a cholesterol-lowering drug, to reduce ongoing lung inflammation after successful tuberculosis TB treatment in adults with and without HIV. This trial is a phase IIB, double-blind, randomized, placebo-controlled study aiming to address persistent lung inflammation detected by PETCT scans, which may contribute to TB relapse and long-term lung problems. The study builds on prior research suggesting statins may help reduce TB burden and lung damage by modulating immune responses and inflammation. Participants are randomly assigned to receive either 40 mg of atorvastatin or a matching placebo daily by mouth for 12 weeks following completion of standard TB treatment. The study compares lung inflammation between these two groups using PETCT imaging to measure total lung glycolysis after the 12-week treatment period. The trial includes adults aged 18 to 65 who have completed successful TB therapy and have no drug-resistant TB or significant co-existing conditions that would interfere with participation. During the study, participants will undergo PETCT scans to assess lung inflammation and provide various samples, including DNA, for research. Researchers will monitor lab tests such as liver and kidney function, blood counts, and HIV-related markers in infected participants. Participants must be willing to follow up regularly and practice effective pregnancy prevention. The main outcome is lung inflammation after treatment, and the total study period involves 12 weeks of treatment with follow-up assessments.

CONDITIONS

Brief Title

Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion

Research Team

F

Friedrich Thienemann, MD

S

Sandra Mukasa, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here